<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719053</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00174702</org_study_id>
    <nct_id>NCT03719053</nct_id>
  </id_info>
  <brief_title>Single Dose Truvada Study</brief_title>
  <official_title>Single Observed Dose Administration of Truvada® to Establish Single Dose Pharmacokinetic Standards in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines tenofovir (TFV) drug concentrations in adults one day after taking a&#xD;
      single dose of Truvada® - a pill used to prevent and treat HIV infection. The results of this&#xD;
      study will be used to improve the (efficacy/accuracy) of a white coat adherence (WCA)&#xD;
      detection test - a blood test that can be used to indicate medication adherence. Participants&#xD;
      will receive one dose of Truvada®, and provide 2 total samples of blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the plasma and peripheral blood mononuclear cells (PBMC) concentrations of TFV&#xD;
      and TFV diphosphate (TFV-DP), respectively, following a single oral dose of Truvada® [300 mg&#xD;
      tenofovir disoproxil fumarate (TDF) in fixed dose combination with emtricitabine (FTC)], the&#xD;
      same formulation used for HIV pre-exposure prophylaxis (PrEP), and in prior benchmarking&#xD;
      adherence studies (HPTN 066). This will be compared to steady-state TFV and TFV-DP&#xD;
      concentrations to more robustly differentiate single dose concentrations from steady-state&#xD;
      concentrations.&#xD;
&#xD;
      This is part of a larger project to determine the frequency of white coat adherence in&#xD;
      several clinical studies where doses are not observed. For purposes of diagnosing WCA with&#xD;
      TDF, the investigators define WCA quantitatively as taking a single dose of TDF preceded by&#xD;
      no doses in the prior week. The investigators will compare TFV and TFV-DP concentrations&#xD;
      following an observed single oral dose of TDF/FTC to steady-state concentrations of TFV and&#xD;
      TFV-DP after daily dosing under observation.&#xD;
&#xD;
      The study plan involves a screening visit to assess eligibility, followed by two study&#xD;
      visits. Visit one involves pre-dose blood testing, followed by a single dose of Truvada.&#xD;
      Visit two occurs 24-hours after visit one, and involves collection of a final post-dose blood&#xD;
      sample. Blood will be assessed for tenofovir and tenofovir analyte concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Tenofovir (TFV) concentration in ng/mL</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Blood Mononuclear Cells (PBMC) TFV diphosphate (TFV-DP) concentration in femtomole per million cells (fmol/10^6)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Medication Adherence</condition>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.</description>
    <arm_group_label>Truvada</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy with no acute medical illness&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  Age 18 years of age or older&#xD;
&#xD;
          -  Negative qualitative urine pregnancy test at screening and on day of dosing, prior to&#xD;
             dosing, female participants only&#xD;
&#xD;
          -  HIV-1 negative at screening, as documented by Combo Ag/Ab HIV-1/HIV-2 immunoassay&#xD;
&#xD;
          -  At screening, no evidence of hepatic or renal impairment [creatinine clearance &gt; 60&#xD;
             ml/min, total bilirubin ≤ upper limit of normal (ULN), alanine aminotransferase (ALT)&#xD;
             and aspartate aminotransferase (AST) &lt; 1.5 ULN]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant antiretroviral or other medication use, for which there is a known risk of&#xD;
             pharmacokinetic or pharmacodynamic drug interactions.&#xD;
&#xD;
          -  Active medical or psychological condition that, in the opinion of the investigator,&#xD;
             might put the volunteer at undue risk or interfere with the participation of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Hendrix</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

